Search Results - "Karol, Michael D"

Mass balance and pharmacokinetics of an oral dose of 14C‐napabucasin in healthy adult male subjects by Dai, Xiaoshu, Karol, Michael D., Hitron, Matthew, Hard, Marjie L., Blanchard, John Evan, Eraut, Nicola C. J. E., Rich, Natalie, Gufford, Brandon T.

“…This phase 1, open‐label study assessed14C‐napabucasin absorption, metabolism, and excretion, napabucasin pharmacokinetics, and napabucasin metabolites…”
Get full text

Influence of cardiac output on dexmedetomidine pharmacokinetics by Dutta, S, Lal, R, Karol, M D, Cohen, T, Ebert, T

“…Dexmedetomidine, a highly selective alpha(2)-adrenoceptor agonist, reduces the requirements for anesthetic, analgesic, sedative, and hypnotic drugs…”
Get more information

Effect of dexmedetomidine on propofol requirements in healthy subjects by Dutta, S, Karol, M D, Cohen, T, Jones, R M, Mant, T

“…Dexmedetomidine-propofol pharmacodynamic interaction was evaluated in nine healthy subjects in a crossover design. Dexmedetomidine/placebo was infused using a…”
Get more information

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies by Goldman, Jonathan W, Raju, Robert N, Gordon, Gregory A, El-Hariry, Iman, Teofilivici, Florentina, Vukovic, Vojo M, Bradley, Robert, Karol, Michael D, Chen, Yu, Guo, Wei, Inoue, Takayo, Rosen, Lee S

“…This phase I study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics and antitumor activity of ganetespib in patients with solid…”
Get full text

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics by DeAngelo, Daniel J., Stone, Richard M., Heaney, Mark L., Nimer, Stephen D., Paquette, Ronald L., Klisovic, Rebecca B., Caligiuri, Michael A., Cooper, Michael R., Lecerf, Jean-Michel, Karol, Michael D., Sheng, Shihong, Holford, Nick, Curtin, Peter T., Druker, Brian J., Heinrich, Michael C.

“…Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3),…”
Get full text

A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma by Goyal, Lipika, Wadlow, Raymond C., Blaszkowsky, Lawrence S., Wolpin, Brian M., Abrams, Thomas A., McCleary, Nadine Jackson, Sheehan, Susan, Sundaram, Eamala, Karol, Michael D., Chen, John, Zhu, Andrew X.

“…Summary Background Ganetespib (STA-9090) is an Hsp90 inhibitor that downregulates VEGFR, c-MET, HER2, IGF-IR, EGFR, and other Hsp90 client proteins involved in…”
Get full text

Napabucasin Drug‐Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers by Dai, Xiaoshu, Karol, Michael D., Hitron, Matthew, Hard, Marjie L., Goulet, Matthew T., McLaughlin, Colleen F., Brantley, Scott J.

“…Napabucasin is an orally administered reactive oxygen species generator that is bioactivated by the intracellular antioxidant nicotinamide adenine dinucleotide…”
Get full text

The Effects of Oral Doses of Lansoprazole and Omeprazole on Gastric pH by Tolman, Keith G, Sanders, Steven W, Buchi, Kenneth N, Karol, Michael D, Jennings, Dennis E, Ringham, Gary L

“…We compared gastric pH values after therapeutic doses of lansoprazole and omeprazole in 17 healthy adult men. The pharmacokinetics of the two drugs were…”
Get full text

Mass balance and pharmacokinetics of an oral dose of 14 C-napabucasin in healthy adult male subjects by Dai, Xiaoshu, Karol, Michael D, Hitron, Matthew, Hard, Marjie L, Blanchard, John Evan, Eraut, Nicola C J E, Rich, Natalie, Gufford, Brandon T

“…This phase 1, open-label study assessed C-napabucasin absorption, metabolism, and excretion, napabucasin pharmacokinetics, and napabucasin metabolites (primary…”
Get full text

Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules by Amer, Fouad, Karol, Michael D., Pan, Wei-Jian, Griffin, Janice S., Lukasik, Nancy L., Locke, Charles S., Chiu, Yi-Lin

“…The pharmacokinetic profiles of single doses of lansoprazole 15- and 30-mg sachets for suspension were compared with those of corresponding doses of…”
Get full text

Effects of passive smoking on theophylline clearance by Matsunga, S K, Plezia, P M, Karol, M D, Katz, M D, Camilli, A E, Benowitz, N L

“…Theophylline disposition was examined in seven passive smokers, defined as nonsmokers with long-term exposure to cigarette smoke, and seven age-matched…”
Get more information

Drug-drug interaction (DDI) potential of oral napabucasin in healthy adults by Dai, Xiaoshu, Karol, Michael D., Hitron, Matthew, Hard, Marjie, Goulet, Matthew T., Mclaughlin, Colleen F., Brantley, Scott J.

“…Abstract only 142 Background: Napabucasin is an NQO1-bioactivatable investigational agent hypothesized to affect multiple oncogenic cellular pathways including…”
Get full text

Abstract A113: Mass balance and pharmacokinetics of an oral dose of 14C-napabucasin in healthy adult male subjects by Dai, Xiaoshu, Karol, Michael D, Hitron, Matthew, Hard, Marjie, Blanchard, J Evan, Eraut, Nicola, Rich, Natalie, Gufford, Brandon

“…Abstract Introduction: Napabucasin is an NQO1-bioactivatable investigational agent hypothesized to affect multiple oncogenic cellular pathways including pSTAT3…”
Get full text

Lack of Pharmacokinetic Interaction between Lansoprazole and Intravenously Administered Phenytoin by Karol, Michael D., Locke, Charles S., Cavanaugh, John H.

“…The objective of this randomized, double‐blind, two‐period crossover study was to investigate whether concomitant steady‐state lansoprazole influences the…”
Get full text

Lack of Interaction between Lansoprazole and Propranolol, a Pharmacokinetic and Safety Assessment by Karol, Michael D., Locke, Charles S., Cavanaugh, John H

“…Due to the prevalence of both gastrointestinal and cardiovascular diseases, it is likely that patients may be coprescribed gastric parietal cell proton pump…”
Get full text

Clinical Sevoflurane Metabolism and Disposition by Kharasch, Evan D., Karol, Michael D., Lanni, Carmine, Sawchuk, Ronald

“…Background Sevoflurane has low blood and tissue solubility and is metabolized to free fluoride and hexafluoroisopropanol (HFIP). Although sevoflurane uptake…”
Get full text

Clinical Sevoflurane Metabolism and Disposition by Kharasch, Evan D., Armstrong, Andrew S., Gunn, Kerry, Artru, Alan, Cox, Kathy, Karol, Michael D.

“…Background Sevoflurane is metabolized to free fluoride and hexafluoroisopropanol (HFIP). Cytochrome P450 2E1 is the major isoform responsible for sevoflurane…”
Get full text

Pharmacokinetics and interaction pharmacodynamics of dexmedetomidine in humans by Karol, Michael D., Maze, Mervyn

“…Dexmedetomidine is a potent and highly selective α2-adrenoceptor agonist with a selectivity ratio of 1600:1 (α2:α1). Dexmedetomidine is a highly lipophylic…”
Get full text

DNA binding by antitumor anthracene derivatives by Wunz, Timothy P, Craven, Mary T, Karol, Michael D, Hill, G. Craig, Remers, William A

“…The relative DNA binding strengths of bisantrene and nine new analogues were measured by spectrophotometric titration and melt transition temperature (Tm)…”
Get full text

A phase I and pharmacokinetic study of multiple schedules of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel for subjects with advanced solid tumor malignancies by Kauh, John S., Harvey, R Donald, Owonikoko, Taofeek Kunle, El-Rayes, Bassel F., Shin, Dong Moon, Murali, Sujatha, Lewis, Colleen Margaret, Karol, Michael D., Teofilovici, Florentina, Du, Yuhong, Fu, Haian, Khuri, Fadlo Raja, Ramalingam, Suresh S.

“…Abstract only 3094 Background: Ganetespib is a next-generation Hsp90 inhibitor unrelated to the first-generation ansamycin class of Hsp90 inhibitors and has…”
Get full text